Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
25. Januar 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
24. Januar 2023 21:19 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
23. Januar 2023 16:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
22. Januar 2023 14:00 ET
|
Pliant Therapeutics, Inc.
Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease...
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
15. Dezember 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily,...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
15. November 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
08. November 2022 16:02 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
05. Oktober 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
15. September 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel...